Navigation Links
BioNeutral Group Expands The Testing Of Its Ygiene Sterilant Against Anthrax Spores

MORRISTOWN, N.J., July 3, 2012 /PRNewswire/ -- BioNeutral Group, Inc. (OTCBB: BONU) a specialty life science technology based company announced today that it has contracted Battelle to test its Ygiene Sterilants against Bacillus anthracis Ames Spores. These tests are designed to determine the efficacy of Ygiene under conditions which simulate actual contaminated environments and to determine applicability for military and homeland security utilization. Testing is expected to commence shortly.

BioNeutral's Dr. Andy Kielbania said, "We are extremely pleased to have the opportunity to work with  a well-known organization like Battelle. We believe this non-clinical laboratory testing of our Ygiene Sterilants is a critical step in moving our product line into highly specialized applications. The results from this study along with our association with DLA Piper and Senator Daschle will allow us to properly position our products for government applications."

About Battelle

Battelle is the world's largest private, independent research and development organization. For more information see

About BioNeutral Group, Inc.

Headquartered in Morristown, New Jersey with lab facilities at the New Jersey Institute of Technology in Newark, Inc., is a specialty technology-based life-science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. Auto Neutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit  

Find us on Facebook:  

Follow us on Twitter:  

Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are available for sale in the United States.

SOURCE BioNeutral Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutral Group Appoints A New Member to the Board of Directors
2. BioNeutral Group Receives $400,000 in Equity Financing
3. Foundation Venture Capital Group Makes Eighth Start-Up Investment
4. Hark! Group demonstrates first heralded single photon source made from silicon
5. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
6. aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group
7. Nitor Group Demonstrates Direct Product Suite at Direct Implementation and Adoption Summit May 31-June 1
8. Mindray Renews Agreement with HealthTrust Purchasing Group, L.P. to Provide Patient Monitoring Equipment
9. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
10. MiMedx Group Announces Record First Quarter Results
11. SOCMA Announces Launch of SCD-iBIO Group
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing of ... team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... sale of broadly enabling, pressure cycling technology ("PCT")-based sample ... announced it has received gross proceeds of $745,000 from ... (the "Offering"), increasing the total amount raised to date ... closings are expected in the near future. ...
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
Breaking Biology News(10 mins):